Compare Morenzo Abadi Perkasa Tbk. (ENZO) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Morenzo Abadi Perkasa Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Morenzo Abadi Perkasa Tbk. trades at Rp78 (market cap 162.19B, 121.54M 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Morenzo Abadi Perkasa Tbk. is the larger of the two by market cap. Which is the better fit depends on your goals.
| ENZO | SCPI | |
|---|---|---|
Market Cap | 162.19B | 104.4B |
Volume | 121.54M | — |
Lot | 1.22M | — |
Turnover | 9.5B | — |
Average Price | 78.21 | — |
Value | 9.5B | — |
Indicative Equilibrium Price | 78 | — |
Indicative Equilibrium Volume | 28.2K | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Morenzo Abadi Perkasa Tbk.
PT Morenzo Abadi Perkasa Tbk, (The “Company”) was established based on Notarial Deed No. 21 of Jhon Langsung, S.H., dated January 10, 2013. Company commenced its commercial business activities in 2013. PT Tritunggal Sukses Investama is the ultimate Parent Entity and Parent Entity of the Company and Mr. Markus Silitonga as the ultimate shareholder.
Read more on ENZO →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
